BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 28457954)

  • 1. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
    West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
    J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
    Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
    J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.
    VanDevanter DR; Heltshe SL; Spahr J; Beckett VV; Daines CL; Dasenbrook EC; Gibson RL; Raksha J; Sanders DB; Goss CH; Flume PA;
    J Cyst Fibros; 2017 Sep; 16(5):607-615. PubMed ID: 28438499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.
    Heltshe SL; West NE; VanDevanter DR; Sanders DB; Beckett VV; Flume PA; Goss CH;
    Contemp Clin Trials; 2018 Jan; 64():35-40. PubMed ID: 29170074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
    Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
    Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
    Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
    Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of pulmonary exacerbation treatment in cystic fibrosis.
    Sanders DB; Ostrenga JS; Rosenfeld M; Fink AK; Schechter MS; Sawicki GS; Flume PA; Morgan WJ
    J Cyst Fibros; 2020 May; 19(3):407-414. PubMed ID: 31257102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
    Thornton CS; Caverly LJ; Kalikin LM; Carmody LA; McClellan S; LeBar W; Sanders DB; West NE; Goss CH; Flume PA; Heltshe SL; VanDevanter DR; LiPuma JJ
    Ann Am Thorac Soc; 2024 Apr; 21(4):595-603. PubMed ID: 37963297
    [No Abstract]   [Full Text] [Related]  

  • 9. Correspondence between symptoms and preference-based health status measures in the STOP study.
    Gold LS; Patrick DL; Hansen RN; Beckett V; Goss CH; Kessler L
    J Cyst Fibros; 2019 Mar; 18(2):251-264. PubMed ID: 30170756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis.
    Schultz A; McLeod C; Berry S; Marsh J; McKenzie A; Messer M; Wood J; Saville B; Jaffe A; Ranganathan S; Stick S; Wark P; Webb S; Snelling T
    Trials; 2023 Mar; 24(1):211. PubMed ID: 36949472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
    VanDevanter DR; Morris NJ; Konstan MW
    J Cyst Fibros; 2016 May; 15(3):372-9. PubMed ID: 26603642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
    VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
    J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.
    Waters V; Stanojevic S; Klingel M; Chiang J; Sonneveld N; Kukkar R; Tullis E; Ratjen F
    J Cyst Fibros; 2015 Nov; 14(6):770-6. PubMed ID: 26265220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic duration and changes in FEV
    Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
    BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.
    Wagener JS; Rasouliyan L; VanDevanter DR; Pasta DJ; Regelmann WE; Morgan WJ; Konstan MW;
    Pediatr Pulmonol; 2013 Jul; 48(7):666-73. PubMed ID: 22888106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
    McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH
    Ann Am Thorac Soc; 2024 May; 21(5):716-726. PubMed ID: 38096105
    [No Abstract]   [Full Text] [Related]  

  • 17. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
    Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
    BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis.
    Rayment JH; Stanojevic S; Davis SD; Retsch-Bogart G; Ratjen F
    Thorax; 2018 May; 73(5):451-458. PubMed ID: 29449440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.
    Castner LM; Zimbric M; Cahalan S; Powell C; Caverly LJ
    J Cyst Fibros; 2021 Nov; 20(6):926-931. PubMed ID: 33612403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.
    Klingel M; Stanojevic S; Tullis E; Ratjen F; Waters V
    Ann Am Thorac Soc; 2019 Jul; 16(7):861-867. PubMed ID: 30874447
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.